Metacrine (Metacrine) Change In Other Working Capital : $-0.39 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Metacrine Change In Other Working Capital?

Metacrine's Change In Other Working Capital for the quarter that ended in Sep. 2022 was $0.00 Mil. It means Metacrine's Other Working Capital increased by $0.00 Mil from Jun. 2022 to Sep. 2022 .

Metacrine's Change In Other Working Capital for the fiscal year that ended in Dec. 2021 was $-0.74 Mil. It means Metacrine's Other Working Capital declined by $0.74 Mil from Dec. 2020 to Dec. 2021 .

Metacrine Change In Other Working Capital Historical Data

The historical data trend for Metacrine's Change In Other Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metacrine Change In Other Working Capital Chart

Metacrine Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Change In Other Working Capital

-1.97

-0.51

-0.60

-0.74

Metacrine Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Change In Other Working Capital	Get a 7-Day Free Trial										-0.19	-0.19	-0.20	-	-

Metacrine Change In Other Working Capital Calculation

Change In Other Working Capital is any increase or decrease between periods of other working capital that are not otherwise classified.

Change In Other Working Capital for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39 Mil.

Metacrine Change In Other Working Capital Related Terms

Thank you for viewing the detailed overview of Metacrine's Change In Other Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Metacrine (Metacrine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metacrine Inc (OTCPK:MTCR) » Definitions » Change In Other Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

3985 Sorrento Valley Boulevard, Suite C, San Diego, CA, USA, 92121

Website

https://www.metacrine.com

Metacrine Inc is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients with liver and gastrointestinal diseases. Its program targets the farnesoid X receptor, or FXR, which is central to modulating liver and GI diseases. Its FXR product candidates include MET409 and MET642.

Executives

Michael York	officer: Chief Business Officer	C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PKWY., SUITE 30, MALVERN PA 19355
Preston Klassen	director, officer: President & CEO	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Hubert C Chen	officer: Chief Medical Officer	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Julia C. Owens	director	C/O OVASCIENCE, INC., 9 FOURTH AVENUE, WALTHAM MA 02451